502 related articles for article (PubMed ID: 21892191)
1. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
[TBL] [Abstract][Full Text] [Related]
2. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Choi JH; Banks AS; Estall JL; Kajimura S; Boström P; Laznik D; Ruas JL; Chalmers MJ; Kamenecka TM; Blüher M; Griffin PR; Spiegelman BM
Nature; 2010 Jul; 466(7305):451-6. PubMed ID: 20651683
[TBL] [Abstract][Full Text] [Related]
4. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
5. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
7. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
[TBL] [Abstract][Full Text] [Related]
9. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
10. Trichostatin A modulates thiazolidinedione-mediated suppression of tumor necrosis factor α-induced lipolysis in 3T3-L1 adipocytes.
Lu JC; Chang YT; Wang CT; Lin YC; Lin CK; Wu ZS
PLoS One; 2013; 8(8):e71517. PubMed ID: 23951179
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
13. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.
Kershaw EE; Schupp M; Guan HP; Gardner NP; Lazar MA; Flier JS
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1736-45. PubMed ID: 17848638
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
[TBL] [Abstract][Full Text] [Related]
16. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
17. Obesity: New life for antidiabetic drugs.
Houtkooper RH; Auwerx J
Nature; 2010 Jul; 466(7305):443-4. PubMed ID: 20651677
[TBL] [Abstract][Full Text] [Related]
18. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
Milton FA; Cvoro A; Amato AA; Sieglaff DH; Filgueira CS; Arumanayagam AS; de Lima Mdo C; Pitta IR; de Assis Rocha Neves F; Webb P
Biochem Biophys Res Commun; 2015 Aug; 464(3):718-23. PubMed ID: 26168725
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological repression of PPARγ promotes osteogenesis.
Marciano DP; Kuruvilla DS; Boregowda SV; Asteian A; Hughes TS; Garcia-Ordonez R; Corzo CA; Khan TM; Novick SJ; Park H; Kojetin DJ; Phinney DG; Bruning JB; Kamenecka TM; Griffin PR
Nat Commun; 2015 Jun; 6():7443. PubMed ID: 26068133
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
